top of page
All News
Thai FDA approves NUZOLVENCE® (zoliflodacin) just six months after US authorizationAdvancing faster access to a much-needed new treatment for gonorrhoea
The GARDP Foundation (known as GARDP) and Dr. Reddy's Laboratories today announced that the Thai Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin), a first-in-class oral antibiotic for the treatment of uncomplicated urogenital gonorrhoea. The approval follows a priority review submission led by Dr. Reddy's Laboratories, with support from GARDP. NUZOLVENCE® is indicated for the treatment of uncomplicated urogenital gonorrhoea due to Neisseria gonorrhoe
Jul 284 min read
Thailand Registers Ravidasvir, a Simple-to-Use and Effective Antiviral for Hepatitis C, Expanding Treatment Options for Thai Patients
Thailand’s Food and Drug Administration (FDA) has approved ravidasvir as a safe and effective treatment against hepatitis C following clinical trials conducted in Thailand and Malaysia. Ravidasvir is approved for use in combination with another antiviral called sofosbuvir. The oral combination treatment is taken once daily for 12 weeks. The combination of ravidasvir and sofosbuvir—two direct-acting antivirals—was shown in clinical studies to be safe and effective, including i
Apr 283 min read
bottom of page